Abstracts by keywords: DLBCL
The malignant tumor disease of diffuse large-cell B-cell lymphoma (DLBCL), which originates from immune cells, is considered the most common non-Hodgkin's lymphoma in adults, with around 30 to 58% (Tilly et. al 2015: p. 116). With a two-year incidence of 3.8 cases per 100,000 inhabitants, it is the most common malignant disease of the lymphatic system in Europe (Sant et al. 2010: 3728). The incidence increases with age, with a median of 70 years (Morton et al. 2006: 265). In addition to an enlargement of the lymph nodes, the spleen can also be affected. Lymphomas often have an aggressive course. If left untreated, DLBCL can be fatal. Due to a high histological, clinical and molecular variability, the mean survival time varies greatly. The 5-year survival rates are given as 60-90% (Ärztezeitung 2021), although survival is worse, especially if there is no response to 1L therapy (AWMF online 2022). In the therapy, among other things, autologous or allogeneic stem cell transplants (STZ) are carried out; the expenses amount to between 107,457 euros and 230,399 euros per patient (Mayerhoff et al. 2019: 126). There are now newly approved treatment options in Germany that are intended to enable patients to survive longer. In August 2018, the treatment method of CAR-T cell therapy (chimeric antigen receptor on T cells) was approved in the European Union after 2L or more lines of therapy. This is a cancer immunotherapy based on genetically modified T cells with synthetic antigen-specific receptors (Srivastava/Riddell 2015: 494). Furthermore, especially in 1L and 2L, immunochemotherapies or classic chemotherapy are used, often in the form of complex treatment regimens and sometimes in combination with rituximab (RTX). Due to these complex treatment options, there is a need for scientific evidence on care.